Literature DB >> 27245483

Health-related quality of life in adolescent survivors of bronchopulmonary dysplasia.

Sara Bozzetto1, Silvia Carraro1, Lisanna Tomasi1, Mariangela Berardi1, Stefania Zanconato1, Eugenio Baraldi1.   

Abstract

BACKGROUND AND
OBJECTIVE: Bronchopulmonary dysplasia (BPD) is the most common chronic lung disease of infancy in the developed countries. Outcomes for BPD patients have traditionally been assessed using physiological parameters such as lung function, and no data are available on the health-related quality of life (HRQOL) for adolescents with BPD. The aim of this study was to assess HRQOL in adolescents with BPD, in comparison with age-matched and sex-matched control groups of healthy volunteers and asthmatic subjects.
METHODS: We enrolled 27 BPD patients (age range 11-19 years), 27 asthmatic patients and 27 healthy controls. HRQOL was assessed by the Short Form 36 (SF-36) questionnaire. Lung function was assessed by spirometry.
RESULTS: The BPD group did not differ significantly from the healthy controls in any scale or dimension of the SF-36 (the BPD group's summary scores were as follows: physical component summary mean 55.6 + 4.98 and mental component summary 51.8 + 7.75 vs 55.8 + 6.25 and 49.2 + 9.45 for the healthy control group, P > 0.5 and P = 0.26, respectively). Asthmatic adolescents scored lower than those of both healthy controls and patients with BPD in several SF-36 dimensions despite adolescents with BPD having lower lung function. No correlation emerged between lung function and HRQOL in BPD subjects.
CONCLUSION: Despite their impaired lung function, BPD patients have an HRQOL comparable with healthy peers and better than asthmatic patients. We did not find any association between HRQOL and lung function parameters.
© 2016 Asian Pacific Society of Respirology.

Entities:  

Keywords:  Short Form 36 questionnaire; asthma; bronchopulmonary dysplasia; health-related quality of life; paediatrics

Mesh:

Year:  2016        PMID: 27245483     DOI: 10.1111/resp.12811

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  2 in total

1.  Aerosolized deferoxamine administration in mouse model of bronchopulmonary dysplasia improve pulmonary development.

Authors:  Yanru Chen; Sha Gao; Yufei Yan; Jihong Qian; Hao Chen
Journal:  Am J Transl Res       Date:  2018-01-15       Impact factor: 4.060

2.  Development and construct validation of a parent-proxy quality of life instrument in children with bronchopulmonary dysplasia aged 4-8 years old.

Authors:  Lysbert Meijer-Schaap; Anthony E J Dubois; Boudewijn J Kollen; Jet Tijmens-van der Hulst; Bertine M J Flokstra-de Blok; Elianne J L E Vrijlandt
Journal:  Qual Life Res       Date:  2018-10-22       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.